- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Cala Announces FDA Clearance of Next-Gen Tremor Therapy Wearable
The Cala kIQ Plus device provides new therapy modes and adaptive calibration to optimize tremor relief for essential tremor and Parkinson's disease.
Apr. 16, 2026 at 3:21am
Got story updates? Submit your updates here. ›
A next-generation wearable device leverages advanced neurostimulation technology to provide personalized relief for debilitating hand tremors.San Mateo TodayCala, a bioelectronic medicine company, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Cala kIQ Plus system, the next-generation of its wearable neurostimulation device for action hand tremor in essential tremor (ET) and Parkinson's disease (PD). The Cala kIQ Plus introduces new therapy modes and adaptive calibration designed to optimize tremor relief and personalize treatment, providing patients with an intuitive experience whenever tremor control is needed.
Why it matters
Cala's wearable neuromodulation technology aims to transform the standard of care for chronic tremor conditions like essential tremor and Parkinson's disease. The Cala kIQ Plus represents an advancement in their TAPS (Transcutaneous Afferent Patterned Stimulation) therapy, which provides targeted electrical stimulation to help manage debilitating hand tremors that can significantly impact a patient's quality of life and ability to perform daily activities.
The details
The Cala kIQ Plus system builds upon the company's previous Cala kIQ device, which was the first FDA-cleared wearable device to deliver effective therapy for action hand tremor in people with essential tremor and Parkinson's disease. The new Cala kIQ Plus introduces additional therapy modes and adaptive calibration features designed to further optimize tremor relief and personalize the treatment experience for patients.
- The Cala kIQ Plus system received FDA clearance in April 2026.
- Cala will present clinical study data on the Cala kIQ Plus at the American Academy of Neurology conference in Chicago on April 20, 2026.
The players
Cala
A bioelectronic medicine company that is transforming the standard of care for chronic disease through its wearable neuromodulation therapies.
Deanna Harshbarger
The CEO of Cala, who stated that the Cala kIQ Plus system gives patients more control over how, when and where TAPS Therapy is delivered for tremor management.
What they’re saying
“Cala continues to elevate the patient experience and therapy outcomes by advancing wearable neuromodulation technology that treats action hand tremor in essential tremor and Parkinson's disease. The Cala kIQ Plus system gives patients more control over how, when and where TAPS Therapy is delivered for tremor management.”
— Deanna Harshbarger, CEO, Cala
What’s next
Cala will present clinical study data on the Cala kIQ Plus at the American Academy of Neurology conference in Chicago on April 20, 2026, showcasing the device's improved efficacy with new therapy modes.
The takeaway
The Cala kIQ Plus represents a significant advancement in wearable neuromodulation technology for managing debilitating hand tremors associated with essential tremor and Parkinson's disease. By introducing new therapy modes and adaptive calibration features, Cala aims to further optimize tremor relief and provide patients with a more personalized and intuitive treatment experience.
